CureVac Statistics
Total Valuation
CureVac has a market cap or net worth of $783.59 million. The enterprise value is $388.35 million.
| Market Cap | 783.59M |
| Enterprise Value | 388.35M |
Important Dates
The next estimated earnings date is Tuesday, May 28, 2024, before market open.
| Earnings Date | May 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CureVac has 223.88 million shares outstanding. The number of shares has increased by 17.68% in one year.
| Shares Outstanding | 223.88M |
| Shares Change (YoY) | +17.68% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 45.27% |
| Owned by Institutions (%) | 21.67% |
| Float | 122.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 9.17 |
| PS Ratio | 13.12 |
| Forward PS | 12.61 |
| PB Ratio | 1.39 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.57, with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.57 |
| Quick Ratio | 2.25 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -103.28 |
Financial Efficiency
Return on equity (ROE) is -41.90% and return on invested capital (ROIC) is -49.07%.
| Return on Equity (ROE) | -41.90% |
| Return on Assets (ROA) | -29.70% |
| Return on Capital (ROIC) | -49.07% |
| Revenue Per Employee | $59,791 |
| Profits Per Employee | -$289,364 |
| Employee Count | 999 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 5.10 |
Taxes
In the past 12 months, CureVac has paid $215,416 in taxes.
| Income Tax | 215,416 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.65% in the last 52 weeks. The beta is 2.51, so CureVac's price volatility has been higher than the market average.
| Beta (1Y) | 2.51 |
| 52-Week Price Change | -61.65% |
| 50-Day Moving Average | 2.94 |
| 200-Day Moving Average | 5.00 |
| Relative Strength Index (RSI) | 68.85 |
| Average Volume (30 Days) | 751,712 |
Short Selling Information
The latest short interest is 4.39 million, so 1.96% of the outstanding shares have been sold short.
| Short Interest | 4.39M |
| Short Previous Month | 4.19M |
| Short % of Shares Out | 1.96% |
| Short % of Float | 3.60% |
| Short Ratio (days to cover) | 5.32 |
Income Statement
In the last 12 months, CureVac had revenue of $59.73 million and -$289.07 million in losses. Loss per share was -$1.28.
| Revenue | 59.73M |
| Gross Profit | -76.82M |
| Operating Income | -298.33M |
| Pretax Income | -282.84M |
| Net Income | -289.07M |
| EBITDA | -254.68M |
| EBIT | -280.12M |
| Loss Per Share | -$1.28 |
Balance Sheet
The company has $440.75 million in cash and $45.50 million in debt, giving a net cash position of $395.24 million or $1.77 per share.
| Cash & Cash Equivalents | 440.75M |
| Total Debt | 45.50M |
| Net Cash | 395.24M |
| Net Cash Per Share | $1.77 |
| Equity / Book Value | 562.41M |
| Book Value Per Share | 2.51 |
| Working Capital | 317.68M |
Cash Flow
In the last 12 months, operating cash flow was -$291.45 million and capital expenditures -$56.92 million, giving a free cash flow of -$348.37 million.
| Operating Cash Flow | -291.45M |
| Capital Expenditures | -56.92M |
| Free Cash Flow | -348.37M |
| FCF Per Share | -$1.56 |
Margins
Gross margin is -128.61%, with operating and profit margins of -499.45% and -483.96%.
| Gross Margin | -128.61% |
| Operating Margin | -499.45% |
| Pretax Margin | -473.52% |
| Profit Margin | -483.96% |
| EBITDA Margin | -426.38% |
| EBIT Margin | -468.98% |
| FCF Margin | -583.24% |
Dividends & Yields
CureVac does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.68% |
| Shareholder Yield | -17.68% |
| Earnings Yield | -36.89% |
| FCF Yield | -44.46% |
Analyst Forecast
The average price target for CureVac is $6.00, which is 71.92% higher than the current price. The consensus rating is "Hold".
| Price Target | $6.00 |
| Price Target Difference | 71.92% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 40.57% |
| EPS Growth Forecast (5Y) | -14.38% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CureVac has an Altman Z-Score of -1.75 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.75 |
| Piotroski F-Score | 2 |